The goal of this clinical trial is to determine the safety and efficacy of Angiotensin-II in the treatment of pediatric patients in fluid refractory vasodilatory shock. The main questions it aims to answer are:
* To evaluate the change in blood pressure or reduction of vasoactive requirements (norepinephrine equivalent dosing) after initiating Angiotensin II
* To establish the safety and tolerability of Angiotensin-II in pediatric patients Participants will receive Angiotensin-II in addition to standard of care therapy for vasodilatory shock.
* The study team will then monitor the patient's vital signs, blood work, and for any potential side effects from the drug.
* An ultrasound will be performed to look at blood flow through the kidney in the setting of vasodilatory shock.
* A follow up phone call to check in with the patient will be performed 28 days after enrollment.